Biopharmaceutical News and Research

RSS

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. Image credit: Shutterstock.com/Billion Photos

From Aptamer Group 5 Mar 2021

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.

23 Feb 2021

UH receives funding from Gilead Sciences to fight against HIV/AIDS epidemic

A University of Houston Graduate College of Social Work research center working to eradicate the underlying serious and systemic challenges that contribute to the HIV/AIDS epidemic in the Southern United States has received $5 million in renewal funding from biopharmaceutical company Gilead Sciences, Inc. to facilitate the continuation of its impactful work.

22 Feb 2021

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

The Altimmune Inc. vaccine candidate that was tested preclinically at the University of Alabama at Birmingham last year is expected to start patient enrollment for its Phase 1 clinical trial next week.

20 Feb 2021

Can Pfizer and Moderna end the pandemic by sharing their vaccine designs? It’s not that simple

Vaccine makers Pfizer and Moderna earned praise for creating highly effective covid-19 vaccines in record time.

15 Feb 2021

SGD Pharma Takes Lead in Sustainability, Awarded Platinum EcoVadis Rating for The First Time

SGD Pharma, a leading supplier of glass primary packaging in the pharmaceutical industry, has been awarded a ‘platinum’ rating by EcoVadis, positioning it in the top 1% of all companies rated worldwide.

From SGD Pharma 5 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

Gyros Protein Technologies AB today announced the introduction of Gyrolab® Bioaffy™ 4000 CD for immunoassay applications in biotherapeutic workflows.

From Gyros Protein Technologies AB 27 Jan 2021

New discovery could lead to faster and more effective treatments for chronic health complications

A world-first discovery by researchers at Monash University and The University of Queensland could lead to faster and more effective treatments for chronic health complications, such as cardiovascular disease and cancer, with 'fluorescent' in vivo biosensors.

26 Jan 2021

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

FDA takes first steps in bringing clarity to emerging area of individualized drug development

Advances in scientific knowledge and drug development technology have provided an opportunity for new approaches to drug development, including the development of drugs for the treatment of rare diseases.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody.

18 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.

15 Dec 2020

Researchers develop new technology for efficient production of monoclonal antibodies

Proteins in biopharmaceutical productions are usually separated and purificated through the expensive chromatography technique. European researchers are developing an innovative membrane crystallization technology to overcome the issue and make the production of monoclonal antibodies more efficient.

15 Dec 2020

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, leader in innovation and impact, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.

14 Dec 2020

Takeda brings innovative pipeline portfolio to patients for sustained revenue growth

As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade.

From Takeda 10 Dec 2020

Biopharmaceutical News and Research

Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

UH receives funding from Gilead Sciences to fight against HIV/AIDS epidemic

Intranasal COVID-19 vaccine candidate preclinically tested at UAB expected to start clinical trial

Can Pfizer and Moderna end the pandemic by sharing their vaccine designs? It’s not that simple

SGD Pharma Takes Lead in Sustainability, Awarded Platinum EcoVadis Rating for The First Time

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

New discovery could lead to faster and more effective treatments for chronic health complications

CytoDel successfully delivers neuronal antibody in animal models of botulism

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

FDA takes first steps in bringing clarity to emerging area of individualized drug development

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Novel SARS-CoV-2 neutralizing antibody enters Phase 1/2a clinical study

RedHill Biopharma announces promising preliminary results from opaganib study

Phase 2 clinical trial at UCR to test first-in-class drug for treatment of stuttering

Researchers develop new technology for efficient production of monoclonal antibodies

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Takeda brings innovative pipeline portfolio to patients for sustained revenue growth

Pittcon Highlights: Pharmaceutical & Biologic eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News